Company profile
INmune Bio, Inc.
NASDAQ: INMB · Healthcare · Biotechnology
#1081 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
41DFH 26DQ 65GM 39SS 45
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), filing timeliness · ↓ operating margin, net margin
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$45.9M
Employees
21
as of 2026-08-20
Market cap
$59.3M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$50.0k$50.0k2025
Net income-$45.9M-$45.9M2025
Operating income-$47.4M-$47.4M2025
Total assets$32.4M$32.4M2025
Liabilities$8.8M$8.8M2025
Equity$23.5M$23.5M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY18
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is INmune Bio, Inc.’s revenue?
INmune Bio, Inc. booked $50.0k in FY2025 revenue, growing 257% year over year — faster than 91% of Healthcare companies we track, at a -91866.0% net margin.
Peers · Healthcare
HCW Biologics Inc.31DFutureWorld Corp.——Natural Health Farm Holdings Inc.——MultiCell Technologies, Inc.——Ovation Science Inc.23DDIAGNOS Inc.29DNeighbors
Palm Beach →Key facts
CEODavid J. Moss
SectorHealthcare
IndustryBiotechnology
HeadquartersBoca Raton, FL
ExchangeNASDAQ: INMB
Employees21
IPO date2019-02-04
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.